Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864)
On the 22nd Meeting of the third board of directors of the company
Prior approval opinions on relevant matters
As an independent director of Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) (hereinafter referred to as “the company”), based on independent judgment and prudence Responsible attitude, we have fully reviewed the relevant matters considered at the 22nd Meeting of the third board of directors in advance, consulted relevant materials and documents, and made necessary communication with relevant personnel of the company. Now we express the following prior approval opinions:
1、 Prior approval opinions on the renewal of the accounting firm in 2022
After verification, Lixin Certified Public Accountants (special general partnership) has the qualification of securities and futures related business, can independently be competent for the company’s audit work, and can adhere to the independent audit standards in the audit work in 2021. The audit opinions truly and accurately reflect the actual situation of the company. We recognize the company’s continued engagement of Lixin Certified Public Accountants (special general partnership) as the company’s audit institution in 2022, which was submitted to the 22nd Meeting of the third board of directors for deliberation.
2、 Prior approval opinions on the prediction of daily related party transactions of the company in 2022
After verification, the company’s prediction of daily connected transactions in 2022 is based on the company’s normal production and operation needs, follows the fair, fair and open market-oriented principles, and the pricing is fair and reasonable, which is in line with the actual situation of the company’s operation, plays a positive role in the company’s future development, will not affect the company’s independence and will not damage the actual interests of the company, shareholders and small and medium-sized investors. Therefore, we agree to the prediction and submit the proposal on the prediction of the company’s daily connected transactions in 2022 to the 22nd Meeting of the third board of directors for deliberation.
Independent directors: Li Junde, Ren Haiyun, Jiao leipeng
April 26, 2022
